EYPT.US EyePoint, Inc

Healthcare Pharmaceuticals USA Stocks
0.3060 USD
Close of Nov 13, 2026
0.3100 19.11
Market cap
USD 25.7M
P/E
-
P/B
0.17x
ROE
-337.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is EYPT.US undervalued?

Graham number

The Graham number of EyePoint, Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

EyePoint, Inc fundamental analysis

No fundamental analysis for EyePoint, Inc yet.

EyePoint, Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About EyePoint, Inc

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase…

Full company profile